Researchers at Johns Hopkins Medicine, in collaboration with researchers at the National Institutes of Health, report that two new studies in mice with a humanized immune system and human cell lines have identified an enzyme ...
Jul 6, 2023
0
20
International migrants in Australia and beyond are at increased risk of HIV infection due to reduced access to a highly effective prevention measure, a world-first global review led by Monash University has found.
Jul 6, 2023
0
18
For nearly three decades, daily antiretroviral pills have offered patients living with HIV a highly effective way to keep their infection under control.
Jul 5, 2023
0
16
A study of publicly insured adults living with HIV found that long-acting injectable antiretroviral therapy (LA-ART) with cabotegravir (CAB) and rilpivirine (RPV) achieved virologic suppression among most people with detectable ...
Jul 3, 2023
0
3
Animal research is pointing toward a new way to prevent HIV infection: a refillable implant that continuously delivers antiretroviral medications for up to 20 months at a time.
Jun 29, 2023
1
15
The COVID-19 pandemic had substantial psychological impacts on the nation and around the world. New research shows patients with HIV were particularly susceptible to psychosocial challenges like depression, anxiety, substance ...
Jun 29, 2023
0
1
An article published in the journal Biomedicine & Pharmacotherapy demonstrates the beneficial effects of consuming 500 milligrams (mg) per day of propolis for people living with HIV, the virus that causes AIDS. The authors ...
Jun 27, 2023
0
43
It's been over a decade since the FDA approved the first Pre-Exposure Prophylaxis (PrEP) medication for HIV prevention in 2012. Now available in the U.S. as a daily pill or every-two-months injection, the antiretroviral treatment ...
Jun 27, 2023
0
10
Africa's contribution to global HIV research is relatively low compared to its burden of infection, according to a study published online June 22 in PLOS Global Public Health.
Jun 26, 2023
1
1
For patients with HIV without genotype information, a second-line switch to dolutegravir is noninferior to a regimen containing a ritonavir-boosted protease inhibitor (PI), according to a study published in the June 22 issue ...
Jun 23, 2023
0
2
